A unique synthetic single domain antibodies company
Our History
2021
January
Setting up a support agreement with the Institut Curie.
2021
December
Setting up an incubation agreement with Paris Biotech Santé.
2022
July
Winner of the 24th i-Lab innovation competition.
2023
July
Creation of Emglev Therapeutics.
2023
September
Project selected by the CCSP evaluation committee.
2021
January
Setting up a support agreement with the Institut Curie.
2021
December
Setting up an incubation agreement with Paris Biotech Santé.
2022
July
Winner of the 24th i-Lab innovation competition.
2023
July
Creation of Emglev Therapeutics.
2023
September
Project selected by the CCSP evaluation committee.
Our Mission
At Emglev Therapeutics, we have assembled a team of experienced, interdisciplinary founders with strong, complementary expertise in business development and licensing, antibody discovery and cancer biology.
While immunotherapies have revolutionized oncology, several hurdles stand in the way of the conventional antibody discovery process, and their use in the development of immunotherapies for the treatment of solid tumors poses a challenge to medicine.
Emglev’s mission is to overcome current limitations by using its unique proprietary platform of next-generation synthetic antibodies to discover and develop transformative immunotherapies to address unmet medical needs in oncology.
Solid tumors represent approximatively 90% of adult human cancers.
Take a look at our unique technology !
Our Team
Christelle MASDEU
CEO – Business Development and Licensing
- 15+ experience in Academia and Biotech industry
- Proven track record of bringing deals and in licensing-out technologies
- PhD in Cancer Biology, Paris XI University
Sandrine
MOUTEL
MOUTEL
CSO – Antibodies Engineering
- 25+ experience in antibody engineering
- Manager of antibody platform at Institut Curie
- Institut Curie arwarded 2018
- Ph.D in engineering antibodies
Franck Perez
Scientific Board Member – Cell Biology and Antibody Development
- 25+ experience in cell biology and recombinant antibody development
- Co-founder of 3 start-ups (Honing, Mnemo, Twinckle)
- Director of the “Cell Biology and Cancer” Unit at Institut Curie
- Ph.D in Genetics and Cellular Biology
Jean-Christophe Rain
Scientific Board Member – Single Domain Antibodies
- 25+ experience in in vivo and in vitro Molecular Selection
- Co-Founder and now CEO of Hybrigenics Services
- Ph.D in Molecular Genetics, Paris XI University
© Copyright 2023 Emglev Therapeutics. All rights reserved